BAJAJ BROKING

Notification
No new Notification messages
Wagons Learning IPO is Open!
Apply for the Wagons Learning IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

11309

211608

BALAXI

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

BALAXI PHARMA LTD performance

Today’s low

Today’s high

₹ 55.00 ₹ 57.08
₹ 55.16

52 week low

52 week high

₹ 50.42 ₹ 151.45
₹ 55.16

Open Price

₹ 56.96

Prev. Close

₹ 56.96

Volume (Shares)

114677.00

Total traded value

₹ 63.25

Upper Circuit

₹ 68.35

Lower Circuit

₹ 45.56

info

BALAXI PHARMA LTD Share Price Update

As of the latest trading session, BALAXI PHARMA LTD share price is currently at ₹ 55.4, which is down by ₹ -1.55 from its previous closing. Today, the stock has fluctuated between ₹ 55.00 and ₹ 57.08. Over the past year, BALAXI PHARMA LTD has achieved a return of -54.89 %. In the last month alone, the return has been -17.65 %. Read More...

BALAXI PHARMA LTD fundamentals


  • Market cap (Cr)

    60.37

  • P/E Ratio (TTM)

    72.58

  • Beta

    1.12

  • Book Value / share

    23.05

  • Return on equity

    3.42%

  • EPS (TTM)

    0.76

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    1.74

info icon alternate text
  • Market cap (Cr)

    0.0

  • P/E Ratio (TTM)

    0.0

  • Beta

    0.0

  • Book Value / share

    0.0

  • Return on equity

    0.0%

  • EPS (TTM)

    0.0

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    0.0

info icon alternate text

BALAXI PHARMA LTD Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 11.16
Operating Expense 11.74
Net Profit 1.74
Net Profit Margin (%) 15.59
Earnings Per Share (EPS) 0.32
EBITDA 3.01
Effective Tax Rate (%) 25.32
Particulars SEP 2024 (Values in Cr)
Revenue 21.16
Operating Expense 20.24
Net Profit 1.66
Net Profit Margin (%) 7.84
Earnings Per Share (EPS) 0.30
EBITDA 2.77
Effective Tax Rate (%) 24.54
Particulars JUN 2024 (Values in Cr)
Revenue 19.03
Operating Expense 17.98
Net Profit 1.38
Net Profit Margin (%) 7.25
Earnings Per Share (EPS) 0.25
EBITDA 2.36
Effective Tax Rate (%) 26.98
Particulars MAR 2024 (Values in Cr)
Revenue 15.90
Operating Expense 16.33
Net Profit -0.58
Net Profit Margin (%) -3.64
Earnings Per Share (EPS) -0.55
EBITDA 0.37
Effective Tax Rate (%) -119.23
Particulars DEC 2023 (Values in Cr)
Revenue 12.70
Operating Expense 12.96
Net Profit 0.49
Net Profit Margin (%) 3.85
Earnings Per Share (EPS) 0.48
EBITDA 1.31
Effective Tax Rate (%) 36.36
Particulars MAR 2024 (Values in Cr)
Revenue 70.20
Operating Expense 67.01
Net Profit 3.65
Net Profit Margin (%) 5.19
Earnings Per Share (EPS) 3.55
EBITDA 7.63
Effective Tax Rate (%) 34.58
Particulars MAR 2023 (Values in Cr)
Revenue 108.14
Operating Expense 92.28
Net Profit 16.22
Net Profit Margin (%) 14.99
Earnings Per Share (EPS) 16.17
EBITDA 23.43
Effective Tax Rate (%) 27.75
Particulars MAR 2022 (Values in Cr)
Revenue 101.29
Operating Expense 84.34
Net Profit 14.67
Net Profit Margin (%) 14.48
Earnings Per Share (EPS) 14.67
EBITDA 20.00
Effective Tax Rate (%) 25.53
Particulars MAR 2021 (Values in Cr)
Revenue 86.87
Operating Expense 68.08
Net Profit 15.13
Net Profit Margin (%) 17.41
Earnings Per Share (EPS) 15.13
EBITDA 20.70
Effective Tax Rate (%) 26.50
Particulars MAR 2020 (Values in Cr)
Revenue 45.63
Operating Expense 36.96
Net Profit 6.50
Net Profit Margin (%) 14.24
Earnings Per Share (EPS) 8.12
EBITDA 9.28
Effective Tax Rate (%) 29.88
Particulars MAR 2024 (Values in Cr)
Book Value / Share 181.31
ROE % -25.94
ROCE % 20.69
Total Debt to Total Equity 0.09
EBITDA Margin 18.75
Particulars MAR 2023 (Values in Cr)
Book Value / Share 169.51
ROE % 31.05
ROCE % 37.25
Total Debt to Total Equity 0.06
EBITDA Margin 17.85
Particulars MAR 2022 (Values in Cr)
Book Value / Share 113.16
ROE % 53.51
ROCE % 59.62
Total Debt to Total Equity 0.04
EBITDA Margin 19.97
Particulars MAR 2021 (Values in Cr)
Book Value / Share 64.98
ROE % 82.26
ROCE % 92.56
Total Debt to Total Equity 0.04
EBITDA Margin 19.41
Particulars MAR 2020 (Values in Cr)
Book Value / Share 27.75
ROE % 39.02
ROCE % 56.54
Total Debt to Total Equity 0.00
EBITDA Margin 19.40
Particulars MAR 2024 (Values in Cr)
Book Value / Share 108.07
ROE % 3.42
ROCE % 5.99
Total Debt to Total Equity 0.13
EBITDA Margin 11.04
Particulars MAR 2023 (Values in Cr)
Book Value / Share 80.35
ROE % 21.62
ROCE % 27.93
Total Debt to Total Equity 0.10
EBITDA Margin 21.71
Particulars MAR 2022 (Values in Cr)
Book Value / Share 57.91
ROE % 29.00
ROCE % 37.15
Total Debt to Total Equity 0.05
EBITDA Margin 19.79
Particulars MAR 2021 (Values in Cr)
Book Value / Share 43.25
ROE % 42.40
ROCE % 55.40
Total Debt to Total Equity 0.05
EBITDA Margin 23.98
Particulars MAR 2020 (Values in Cr)
Book Value / Share 28.11
ROE % 41.10
ROCE % 58.43
Total Debt to Total Equity 0.00
EBITDA Margin 20.25
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 62.29
Total Assets 258.34
Total Liabilities 258.34
Total Equity 201.36
Share Outstanding 10897750
Price to Book Ratio 4.59
Return on Assets (%) -0.92
Return on Capital (%) -1.09
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 28.21
Total Assets 239.66
Total Liabilities 239.66
Total Equity 182.87
Share Outstanding 10181250
Price to Book Ratio 6.60
Return on Assets (%) 19.17
Return on Capital (%) 23.63
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 7.19
Total Assets 176.47
Total Liabilities 176.47
Total Equity 113.16
Share Outstanding 10000000
Price to Book Ratio 6.07
Return on Assets (%) 27.00
Return on Capital (%) 40.8
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1.66
Total Assets 99.67
Total Liabilities 99.67
Total Equity 64.97
Share Outstanding 10000000
Price to Book Ratio 12.13
Return on Assets (%) 38.25
Return on Capital (%) 55.56
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 4.00
Total Assets 35.97
Total Liabilities 35.97
Total Equity 27.74
Share Outstanding 10000000
Price to Book Ratio 2.63
Return on Assets (%) 16.96
Return on Capital (%) 22
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 44.06
Total Assets 154.36
Total Liabilities 154.36
Total Equity 121.54
Share Outstanding 10897750
Price to Book Ratio 4.59
Return on Assets (%) 2.36
Return on Capital (%) 2.69
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 17.87
Total Assets 129.72
Total Liabilities 129.72
Total Equity 92.10
Share Outstanding 10181250
Price to Book Ratio 6.60
Return on Assets (%) 12.50
Return on Capital (%) 15.77
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 0.84
Total Assets 81.91
Total Liabilities 81.91
Total Equity 57.91
Share Outstanding 10000000
Price to Book Ratio 6.07
Return on Assets (%) 17.90
Return on Capital (%) 24.51
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 0.47
Total Assets 68.91
Total Liabilities 68.91
Total Equity 43.24
Share Outstanding 10000000
Price to Book Ratio 12.13
Return on Assets (%) 21.95
Return on Capital (%) 32.37
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 3.56
Total Assets 37.90
Total Liabilities 37.90
Total Equity 28.11
Share Outstanding 10000000
Price to Book Ratio 2.63
Return on Assets (%) 17.13
Return on Capital (%) 23.11
Particulars MAR 2024 (Values in Cr)
Net Income 2.01
Cash from Operations 11.54
Cash from Investing -1.04
Cash from Financing 30.25
Net change in Cash 34.07
Free Cash Flow 12.23
Particulars MAR 2023 (Values in Cr)
Net Income 56.92
Cash from Operations 18.16
Cash from Investing -10.56
Cash from Financing 25.51
Net change in Cash 21.02
Free Cash Flow 31.22
Particulars MAR 2022 (Values in Cr)
Net Income 54.52
Cash from Operations 39.73
Cash from Investing -28.44
Cash from Financing -0.16
Net change in Cash 5.53
Free Cash Flow 44.48
Particulars MAR 2021 (Values in Cr)
Net Income 44.32
Cash from Operations 2.59
Cash from Investing -5.97
Cash from Financing 3.64
Net change in Cash -2.32
Free Cash Flow 3.87
Particulars MAR 2020 (Values in Cr)
Net Income 8.79
Cash from Operations -13.29
Cash from Investing -0.18
Cash from Financing 18.09
Net change in Cash 3.87
Free Cash Flow -13.10
Particulars MAR 2024 (Values in Cr)
Net Income 5.58
Cash from Operations 3.24
Cash from Investing 0.46
Cash from Financing 27.55
Net change in Cash 26.18
Free Cash Flow 3.27
Particulars MAR 2023 (Values in Cr)
Net Income 22.45
Cash from Operations -1.65
Cash from Investing -2.29
Cash from Financing 26.39
Net change in Cash 17.03
Free Cash Flow 0.71
Particulars MAR 2022 (Values in Cr)
Net Income 19.69
Cash from Operations 14.57
Cash from Investing -6.87
Cash from Financing -1.63
Net change in Cash 0.37
Free Cash Flow 16.33
Particulars MAR 2021 (Values in Cr)
Net Income 20.59
Cash from Operations 15.89
Cash from Investing -20.03
Cash from Financing 3.49
Net change in Cash -3.08
Free Cash Flow 16.49
Particulars MAR 2020 (Values in Cr)
Net Income 9.18
Cash from Operations -13.62
Cash from Investing -0.28
Cash from Financing 18.09
Net change in Cash 3.44
Free Cash Flow -13.44
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 19.60 1.99 279.41 34.11 / 77.70
BLISS GVS PHARMA LTD 119.00 15.60 1.24 1253.91 92.25 / 184.95
CIPLA LTD 1549.65 25.08 4.41 125155.99 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 260.70 21.60 2.64 767.27 145.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 21.96 6.19 279.41 34.11 / 77.70
AMRUTAJAN HEALTH LTD 692.80 40.61 6.72 2002.93 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8665.50 129.24 31.88 21663.75 5000.00 / 9199.00
BLISS GVS PHARMA LTD 119.00 15.45 1.22 1253.91 92.25 / 184.95

BALAXI PHARMA LTD Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
55.16 -3.16 redarrow
red-green-graph indicator
16 Bearish
0 Bullish
  • 5 Days 57.70
  • 26 Days 62.90
  • 10 Days 59.90
  • 50 Days 64.80
  • 12 Days 60.60
  • 100 Days 70.20
  • 20 Days 62.20
  • 200 Days 80.00
57.34 PIVOT

First Support

56.22

First Resistance

58.08

Second Support

55.48

Second Resistance

59.20

Third Support

54.36

Third Resistance

59.94

RSI

30.25

ADX

28.06

MACD

-2.30

Williams % R

-98.89

Commodity Channel Index (CCI)

-160.50

Date

2025-04-30

Week

89785.00

Same Day

39400.00

Month

335021.00

1 Year

1.12

3 Year

0.83

Over 1 Month

-17.65%

down

Over 1 Year

-54.89%

down

Over 3 Months

-14.09%

down

Over 3 Years

-14.61%

down

Over 6 Months

-38.69%

down

Over 5 Years

30.45%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

BALAXI PHARMA LTD shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
17.96%
Promoter Holdings
65.99%
FII
16.02%
DII
0.02%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Balaxi Overseas Private Limited 3.5E7 (63.4%) Shareholding of Promoter and Promoter Group
Unico Global Opportunities Fund Limited 4577717.0 (8.29%) Public Shareholding
Ebisu Global Opportunities Fund Limited 4268642.0 (7.73%) Public Shareholding
Rajasthan Global Securities Private Limited 1417067.0 (2.57%) Public Shareholding
Kunal Mahendra Bhakta 1028855.0 (1.86%) Public Shareholding
Ashish Maheshwari 903870.0 (1.64%) Shareholding of Promoter and Promoter Group
Amol Anand Mantri 778176.0 (1.41%) Public Shareholding
P P Zibi Jose 617030.0 (1.12%) Public Shareholding
Minoshi Maheshwari 527900.0 (0.96%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

BALAXI PHARMA LTD corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
01 Jul 2022 0.5 Final 04 Jul 2022 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
01 Jul 2022 0.5 Final 04 Jul 2022 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
30 May 2024 10.0 2.0 30 May 2024

Balaxi Pharma Ltd Share Highlights

Balaxi Pharmaceuticals has shown a mixed performance for the quarter ending June 2024. Despite a slight decline in net sales, which dipped by 0.51% year-over-year to Rs 65.62 crore, the company achieved a significant increase in net profit. The net profit soared by 115.67%, reaching Rs 6.48 crore compared to Rs 3.01 crore in the same period last year. Read More... The EBITDA also saw a modest rise of 5.1%, standing at Rs 8.24 crore. This strong profitability, despite flat sales, may positively influence the Balaxi Pharma share price. Investors are likely to view this as a sign of improved operational efficiency and profitability, which could drive future growth. Read Less

Balaxi Pharma Ltd Share Annual Reports

The annual report of Balaxi Pharmaceuticals offers a detailed overview of the company's financial and operational performance over the past fiscal year. It provides insights into revenue streams, cost management, and profitability, which are crucial for understanding the company's overall health and growth prospects. For those tracking the Balaxi Pharma share price, Read More...the annual report is an essential document that sheds light on the company's strategic direction, market positioning, and potential for future growth. It also includes information on the company’s governance practices and sustainability initiatives, providing a comprehensive picture of its operations.  Read Less

Balaxi Pharma Ltd Share Dividend

Balaxi Pharmaceuticals' dividend policy is a key point of interest for investors, particularly given the company's strong net profit growth in the recent quarter. While net sales remained relatively flat, the significant increase in profitability could result in favorable dividend payouts. The Balaxi Pharma share price could be positively impacted by a strong dividend announcement, signaling the company’s commitment to returning value to its shareholders. Investors will be looking closely at the upcoming dividend declaration to gauge the company’s financial stability and its approach to balancing growth with shareholder returns.

BALAXI PHARMA LTD Share Price

Balaxi Ventures Limited was formerly incorporated in the name of 'The Anandam Rubber Company Limited' on September 28, 1942. The Company changed its name from 'The Anandam Rubber Company Limited' to 'Balaxi Ventures Limited' on August 08, 2017. The Company incorporated with a basic objective of running rubber and tea plantations and owns several plantations across South India.

In year 1989 the company sold its entire plantations to meet the emerging business needs and started concentrating in Investments and trading. The company previously was a investment company, but the company during the financial year 2018-19 has commenced the business of International Wholesale Trading of Pharmaceuticals, Builders Hardware and FMCG Products

On 15 March 2017, Balaxi Overseas Private Limited (BOPL) entered into a Share Purchase Agreement (SPA) with the erstwhile promoters of Company (i.e. Mr. Nirej V. Paul, Mr. V. M. Paulose, Dr. Leelamma T. J and Mrs. Jaya Paul) to acquire 1,670,036 Equity Shares representing 54.94% of the paid up share capital of the Company along with the control over the Company, pursuant to which BOPL made an Open Offer under Regulation 3(1) and Regulation 4 of SEBI (SAST) Regulations, 2011. Control and management of the Company was acquired by BOPL on May 04, 2017 and it became the new promoter of Company and their representatives i.e. Mr. Ashish Maheshwari and Mrs. Minoshi Maheshwari became the new Directors of the Company. Simultaneously, erstwhile promoters stepped down as promoters from Company on same day and Mr. Nirej V. Paul and Dr. Leelamma TJ resigned as Managing Director and as Chairperson from the Company, respectively. Under the above said Open Offer, BOPL acquired 3,30,000 equity shares representing 10.86% equity share capital of the Company. On completion of the Open Offer BOPL became the holding and Promoter Company with an aggregate shareholding of 2000036 Equity Shares (ie 65.79%).

The main objects of the company were amended to include activities of International wholesale trading in pharmaceutical, food products and builders' hardware on August 08, 2018. The Company commenced the business of International Wholesale Trading of Pharmaceuticals, Builders Hardware and FMCG products from Financial Year 2018-19.

Further, in February 2019, it kickstarted Food Products business by launching a range of biscuits under the brand YAP'.

The Company expanded its presence by establishing a central distribution warehouse in Guatemala, marking its entry into the third geography. This expansion helped in strengthening the distribution network and a wider customer base in 2019.

In FY 2023, Company started operations in two Latin American Countries, i.e., Honduras and El Salvador and also started operations in
the Central African Republic.

Parent organization Indian Private
NSE symbol BALAXI
Founded 1942
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Balaxi Pharmaceuticals Ltd?

Answer Field

The share price of Balaxi Pharmaceuticals Ltd for NSE is ₹ 55.4 and for BSE is ₹ 0.00.

What is the Market Cap of Balaxi Pharmaceuticals Ltd?

Answer Field

The market cap of Balaxi Pharmaceuticals Ltd for NSE is ₹ 60.37 Cr. and for BSE is ₹ 0.0 Cr. as of now.

What is the 52 Week High and Low of Balaxi Pharmaceuticals Ltd?

Answer Field

The 52 Week High and Low of Balaxi Pharmaceuticals Ltd for NSE is ₹ 151.45 and ₹ 50.42 and for BSE is ₹ 0.00 and ₹ 0.00.

How to Buy Balaxi Pharmaceuticals Ltd share?

Answer Field

You can trade in Balaxi Pharmaceuticals Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Balaxi Pharmaceuticals Ltd?

Answer Field

The 1 year returns on the stock has been -54.89%.

What is the Current Share Price of Balaxi Pharmaceuticals Ltd?

Answer Field

Balaxi Pharmaceuticals Ltd share price is for NSE ₹ 55.4 & for BSE ₹ 0.00 as on Apr 30 2025 03:29 PM.

What is the Market Cap of Balaxi Pharmaceuticals Ltd Share?

Answer Field

The market cap of Balaxi Pharmaceuticals Ltd for NSE ₹ 60.37 & for BSE ₹ 0.0 as on Apr 30 2025 03:29 PM.

What is the P/E Ratio of Balaxi Pharmaceuticals Ltd Share?

Answer Field

As on Apr 30 2025 03:29 PM the price-to-earnings (PE) ratio for Balaxi Pharmaceuticals Ltd share is 72.58.

What is the PB ratio of Balaxi Pharmaceuticals Ltd Share?

Answer Field

As on Apr 30 2025 03:29 PM, the price-to-book (PB) ratio for Balaxi Pharmaceuticals Ltd share is 23.05.

How to Buy Balaxi Pharmaceuticals Ltd Share?

Answer Field

You can trade in Balaxi Pharmaceuticals Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Balaxi Pharmaceuticals Ltd Share on Bajaj Broking App?

Answer Field

To buy Balaxi Pharmaceuticals Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Balaxi Pharmaceuticals Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

What is the Balaxi Pharmaceuticals Share price?

Answer Field

The share price of Balaxi Pharmaceuticals Ltd for NSE is ₹ 110.81 and for BSE is ₹ 0.00.

What is the Market Cap of Balaxi Pharmaceuticals Ltd?

Answer Field

The market cap of Balaxi Pharmaceuticals Ltd for NSE is ₹ 1,20.75 Cr. and for BSE is ₹ 0.0 Cr. as of now.

What is the 52W high & 52W low of Balaxi Pharmaceuticals Share?

Answer Field

The 52 Week High and Low of Balaxi Pharmaceuticals Ltd for NSE is ₹ 151.45 and ₹ 79.99 and for BSE is ₹ 0.00 and ₹ 0.00.

How to buy Balaxi Pharmaceuticals Share?

Answer Field

You can trade in Balaxi Pharmaceuticals Ltd shares with Bajaj Broking by opening a Demat Account.

What is one year return for Balaxi Pharmaceuticals Share?

Answer Field

The 1 year returns on the stock has been 16.86%.

What is the P/E ratio of Balaxi Pharma Share in 2024?

Answer Field

As of August 17, 2024, Balaxi Pharmaceuticals' P/E ratio was 13.4. This is a 61% discount to the median range of 34.67 times for its peers.

What is the PB ratio of Balaxi Pharma Share in 2024?

Answer Field

As of August 17, 2024, Balaxi Pharmaceuticals Ltd.'s price-to-book (PB) ratio was 3. This is considered a low PB ratio.

Who is the CEO of Balaxi Pharma Limited?

Answer Field

Ashish Maheshwari is the Chairman and Managing Director of Balaxi Pharmaceuticals Limited. He is also the founder of Balaxi Pharmaceuticals and the Balaxi Group.

When was Balaxi Pharma established?

Answer Field

Balaxi Pharma was established in 1942.

How to buy Balaxi Pharma Share on Bajaj Broking App?

Answer Field

To buy Balaxi Pharma shares on the Bajaj Broking app, follow these steps:

  • Login to the Bajaj Broking App

  • Click on the Search Icon

  • Search “Balaxi Pharma”

  • Click on the BUY icon

  • Place a buy order specifying the desired quantity of shares.

  • Click BUY again to complete the purchase.

Is Balaxi Pharma debt free?

Answer Field

As of August 15, 2024, Balaxi Pharmaceuticals Ltd. (NSE: BALAXI) has negative net debt, meaning it has more cash and short-term investments than debt. Balaxi's debt to equity (D/E) ratio is 0.1, and it has short-term assets that exceed short-term liabilities. Balaxi also has a high Altman Z-score of 4.21, and its long-term assets exceed long-term liabilities. 

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|